Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Daiichi submits Japanese application for esaxerenone

March 2, 2018 12:32 AM UTC

Exelixis Inc. (NASDAQ:EXEL) said Daiichi Sankyo Co. Ltd. (Tokyo:4568) submitted a regulatory application in Japan for esaxerenone (CS-3150) to treat hypertension, triggering a $20 million milestone payment to the South San Francisco company. The candidate is an oral non-steroidal mineralocorticoid receptor antagonist...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article